[go: up one dir, main page]

WO2010102796A2 - Dispositif d'application de substances actives sur la paroi d'un vaisseau corporel - Google Patents

Dispositif d'application de substances actives sur la paroi d'un vaisseau corporel Download PDF

Info

Publication number
WO2010102796A2
WO2010102796A2 PCT/EP2010/001482 EP2010001482W WO2010102796A2 WO 2010102796 A2 WO2010102796 A2 WO 2010102796A2 EP 2010001482 W EP2010001482 W EP 2010001482W WO 2010102796 A2 WO2010102796 A2 WO 2010102796A2
Authority
WO
WIPO (PCT)
Prior art keywords
distal element
vessel
vessel wall
skin
distal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/001482
Other languages
German (de)
English (en)
Other versions
WO2010102796A3 (fr
Inventor
Ralf Hannes
Ulrich Speck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenox GmbH
Innora GmbH
Original Assignee
Phenox GmbH
Innora GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenox GmbH, Innora GmbH filed Critical Phenox GmbH
Publication of WO2010102796A2 publication Critical patent/WO2010102796A2/fr
Publication of WO2010102796A3 publication Critical patent/WO2010102796A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B2017/320733—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a flexible cutting or scraping element, e.g. with a whip-like distal filament member

Definitions

  • the invention relates to a device for applying active substances to the wall of a body vessel with a catheter, a guide element and a distal element arranged on the guide element, which is suitable and intended to come into contact with the wall of the body vessel after emerging from the catheter.
  • Closures due to arteriosclerotic wall thickening or thrombus deposition or sudden embolic events use catheters which are inserted through a small opening in an artery and at the distal end contain a tool for treatment of the diseased or dysfunctional vessel.
  • Such tools can be pleated balloons that expand and, optionally, stent-stabilize vascular constrictions, self-expanding stents, or cutting instruments for reaming the vessels, lasers, claws for removing thrombi or foreign bodies, or as recently introduced soft brushes that hold a blood clot and, if handled properly, can help remove it from the body.
  • the above instruments have been combined with drugs to acutely support the effect of the medical device on the pharmacological effects of these substances.
  • Medical devices especially those that come in contact with blood, have been provided with anticoagulants.
  • This also applies to the structures described in WO 2006/021407 and WO 2008/034615, which provide effective coatings for fixing thrombi located in the vessel lumen to the medical device for the purpose of thrombus removal or coatings or impregnations with thrombolytically active substances.
  • the goal here is the direct and direct influence of the thrombus, but not the application of drugs to the vessel wall.
  • Another method of local drug treatment of arterial walls is based on the targeted administration of a concentrated solution of a lipophilic active substance into the vessel segment to be treated, either in free flow or in small balloons separated proximally and distally, for the short time of treatment vessels not perfused by blood. In both cases, however, only a weaker effect is achieved and a fairly large proportion of the drug enters the general cycle.
  • Many medical devices have been coated with drugs in the past, but in many cases are not designed to treat the surrounding delicate tissue such as a blood vessel wall but to inhibit blood clotting or to prevent infection of long-term implanted catheters or permanent implants that cause blood clotting or to dissolve blood clots.
  • drug-coated medical devices have been described which serve to inhibit local tumor growth in bone, also using high pressures.
  • vascular diseases are often not restricted to the severely narrowed or closed areas but extend over a long distance, whereby the vessel diameter can vary greatly.
  • Single inflammatory plaques represent a great risk for sudden vascular occlusion by thrombus formation without the prior narrowing of the lumen.
  • Various procedures atherectomy, laser, thrombectomy) of vessel recanalization leave more or less severely injured and irregular vessel walls, mechanically by the usual Balloon dilatation and stent placement should not be further damaged. For all these cases, there is no acute and location-selective treatment method.
  • the distal element is equipped with a soft, adaptable to the vessel wall and atraumatic surface that carries the drug and after exiting the catheter seeks a larger diameter than the maximum vessel diameter in to be treated segment of the body vessel, wherein the larger diameter is caused by elastic forces in the distal element.
  • the invention allows to achieve a much better and more targeted delivery of the drug to the vessel wall in vessels with very irregular diameter and curved course.
  • the distal element must be suitable for coming into contact with the wall of the corresponding body vessel, for the most part a vascular vessel, after exiting the catheter, that is, fitting against the vessel surface over a large area.
  • the large-area contact is important for the transfer of the drug from the surface of the distal element to the vessel wall.
  • the distal element is equipped with a soft, adaptable, atraumatic and flexible surface that carries the active ingredient.
  • the active ingredient means that the surface is coated with the active ingredient, the active ingredient is incorporated into the surface, such as by soaking or Impregnate or that the active ingredient is connected in another way with the surface, such that it can be transferred to the vessel wall.
  • the surface of the distal element is soft and atraumatic, d. H. it should under no circumstances bring about an injury to the vessel wall.
  • Soft, flexible and adaptable means that the distal element can cling to the vessel wall and make a large-area contact.
  • the guide member is a guide wire to which the distal member may be connected or which becomes a part of the distal member in the distal region.
  • the distal element may be formed with a brush, sponge or pile structure.
  • a brush structure consists, for example, of brush-shaped individual filaments or filament bundles which are fastened to a central structure extending in the longitudinal axis, for example a wire or plastic body in the distal region or in an element adjoining the distal region of the guide wire. This may be, for example, a braided element of a plurality of individual wires, in which the individual filaments or filament bundles are woven.
  • the individual bristles or fibers may have any orientation, such as at right angles to the course of the central element, retrogard, distally inclined or in the form of outwardly flared bundles.
  • Suitable materials for the brush, sponge or pile structure are in particular plastics approved for medical use, for example polyethylene, polypropylene, polyamide and polyester. Sponge and pile structures are designed so that they are superficially wettable by the active ingredients and / or can take up the active ingredient in its structure, so that it is transferred to it upon contact with a vessel wall and optionally pressed against it at low pressure.
  • the active ingredient is located in particular at the outer end of the bristles and fibers.
  • the distal element peripherally has a structured and conformable skin extending, for example, over an underlying brush structure.
  • the structured skin can be made of one of the aforementioned materials and have pores or pits on the surface into which the active substance is introduced.
  • the skin may also have a fleece, pile or sponge structure.
  • the enveloping structures in a preferred embodiment are open to the intravascular space or, if they completely enclose a lumen, there is access to a central channel which extends to a port leading outside the patient's body.
  • the structures differ from the known balloons (eg US Pat. No. 7,179,251) in that the connection to the blood or via a channel in the catheter shaft to a container outside the body serves exclusively to equalize the pressure during expansion without the pressure in the interior of the structure exceeding the blood pressure increase.
  • the active ingredient can also be incorporated in the material of the skin, in the fleece, pile or sponge structure, such that it is released over the duration of application to the vessel wall.
  • the skin and the distal element can be present separately, so that the skin with the active substance can be applied first and is pressed by the distal element of the device in the second step against the vessel wall.
  • Skin and distal element of the device thus form a unit according to the invention at the place of use, as well as in the one-piece device.
  • the skin may consist of a conventional material, as used in medicine for similar purposes, for example as a film of polyethylene, polypropylene, polyamide, PTFE or polyester. It is understood that instead of a simple skin, a fleece, pile or sponge structure can be used.
  • the distal element may have a basket structure.
  • the distal element may have a basket structure covered with the above-mentioned structured and conformable skin.
  • the basket structure may for example consist of a self-expanding wire mesh and be made for example of Nitinol. Such basket structures are known per se.
  • the active ingredient is preferably present in a lipophilic matrix, the lipophilic character of which may be determined on the one hand by the active ingredient itself, on the other hand by suitable additives.
  • the partition coefficient between butanol and water is> 1.
  • hydrophilic auxiliaries or active substances In order to improve the detachment or dissolution of sparingly water-soluble active ingredients, it is possible to add hydrophilic auxiliaries or active substances or else solubilizers which are common in pharmacy.
  • the device in its distal region, d. H. especially at the distal element to be provided with radiopaque markers.
  • radiopaque markers Such labeling techniques are known per se.
  • the distal end of the guide wire or the support structure of the distal element is radiopaque or equipped with radiopaque materials.
  • the invention also relates to the use of the device described above as a carrier of active substances which are to be applied to the wall of a body vessel, in particular a blood vessel.
  • Suitable carriers are catheters or other medical devices which are not intended for prolonged (ie> 15 min) or permanent retention in the body, with a distal component which can be introduced into the body, which on the one hand can be expanded without great force and, on the other hand, the changing diameter of For example, it adjusts blood vessels in such a way that it always comes to a wall contact over the entire diameter of the vessel, without the vessel wall is thereby significantly damaged or an existing damage is further aggravated.
  • these products may or may have a mechanical smoothing effect, but without leaving marked vessel wall injuries such as cracks, etc., such as high pressure angioplasty without or with stent placement.
  • Examples of such medical devices are sponges, optionally coated with a thin, permeable and / or structured skin, other soft hollow body with a membrane whose outer surface may be structured or brush or brush-like structures as described for example in WO 2006/021407 and WO 2008 No. 034615 are without or with this enclosing smooth or structured membrane.
  • a membrane whose outer surface may be structured or brush or brush-like structures as described for example in WO 2006/021407 and WO 2008 No. 034615 are without or with this enclosing smooth or structured membrane.
  • flat bands or circular sectors are likewise suitable, and these can be roughened or structured as desired in the area.
  • the outer contour of such example consisting of soft nylon filament brush may be cylindrical, trapezoidal or wedge-shaped, round or otherwise shaped.
  • the drug carriers eg brushes, sponges, membranes mounted on a wire or shaft up to 3 m long become of small cross-section compressed and advanced in this form to the site of treatment or to a somewhat distal location. Only there they are brought into contact either by release from a hose limiting their cross-section or by insufflation with the tissue to be treated. The actual treatment is carried out by withdrawal or advancement of the expanded drug carrier through the area to be treated and / or by rotation of the carrier about the longitudinal axis. If necessary, for the short time of drug transfer from the carrier to the vessel wall, blood flow may be interrupted by means of a balloon located proximally or distally of the drug carrier.
  • a balloon located proximally or distally of the drug carrier.
  • cytostatic active substances are used as they are used for example in tumor therapy systemically or for restenosis prophylaxis on stents or balloon catheters.
  • cytostatics may be used for their anti-inflammatory properties, immunosuppressants, steroidal and non-steroidal anti-inflammatory drugs, statins, antioxidants, anticoagulants or mixtures of individual drugs; a variety of such substances are described in textbooks of pharmacology and numerous patents, z. B. US 2008/0118544 or DE 10 2007 036 685.1.
  • Preferred active ingredients are paclitaxel, docetaxel, protaxel and other taxanes, methotrexate, 2-deoxyglucose, thalidomide, triamcinolone (acetonide), betamethasone (17-monopropionate), dexamethasone and its derivatives, genistein, sirolimus, everolimus and other mTOR inhibitors, atorvastatin, cerivastatin , Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, doxycycline, minocycline, probucol, tocopherols, ascorbic acid, arsenic trioxide and other arsenic salts and compounds, bismuth salts and compounds.
  • the active substances in question are also bound as salts or complex compounds or covalently, for example in the form of prodrugs or in turn effective derivatives can be used. If necessary, mixtures of certain active ingredients can be used, wherein each active ingredient is to be dosed according to its potency.
  • active ingredients are used whose main point of attack is the vessel wall, in contrast to drugs which primarily inhibit or promote blood coagulation or dissolve blood clots or otherwise act on blood components.
  • anticoagulants may additionally be applied to the surfaces of the invention
  • the main effect is not thrombolysis or promoting blood clotting; Rather, the active ingredient groups and active ingredients, insofar as they are disclosed in WO 2006/021407 and WO 2008/034615, may not be included.
  • lipophilic substances or substances having a partition coefficient between physiological NaCl solution and cells for example, isolated vascular smooth muscle cells of ⁇ 1 or good solubility in organic solvents are preferred.
  • the medicaments can be applied to the medical devices in any solid, suspended, emulsified, soluble or otherwise customary pharmaceutical preparation. Preferred is the use on the medical devices in dry form, if necessary after drying, particularly preferred is the use in the form of particles of defined size. These may contain the active compound in pure form, amorphous or crystalline or bound in any manner to particulate carriers or included in particulate structures.
  • Such structures can be solid particles of a substance or mixtures of substances, capsules, liposomes, micelles or drops of liquid as they are part of emulsions.
  • the preferred particle size is between 10 nm and 5 ⁇ m. Larger particles are suitable if they do not cause embolisms due to their solubility or other properties.
  • the dosage of the drugs depends on their potency, the indication and the size of the vascular or tissue area to be treated.
  • the preferred dose on the excipient is in the range from 1000 ⁇ g to 50 mg, the dose delivered per mm 2 vascular wall being usually 0.1-10 ⁇ g, in exceptional cases also up to or even more than 20 ⁇ g.
  • the information for each active substance applies individually.
  • the drugs are present on the carrier either in solid form or dissolved, emulsified, suspended in the form of a viscous, water or blood non-fast and readily miscible liquid, cream or paste, optionally embedded in a suitable matrix.
  • an insertion tube to the place of treatment, for example, a peripheral or cerebral artery, advanced and only released there.
  • the drugs are in solid form, they may be crystals, amorphous particles, specially preformed structures such as microcapsules or thin, non-structured layers on the surface of the supports, or poorly defined layers, such as formed during evaporation of solvents or solvent mixtures ,
  • excipients have been described which improve the chemical stability of the drug, enhance or reduce adhesion to the surface of the carrier, or promote the dissolution of poorly water soluble drugs, or the inclusion of any drugs in the drug Improve tissue and also have utility for the coating of novel supports as described herein; polyvinyl chloride, acrylates, complex polysaccharides (WO 94/23787); Hyaluronic acid, lipids, fibrin glue (USP 6,146,358); Sugars, proteins, numerous phospholipids, cholesterol, amphiphilic substances (US 2003/064965); Oils, triglycerides (esters of 9-15 carbon carboxylic acids), fatty acids, antioxidants (US
  • Preferred auxiliaries for the purposes of the present invention are natural substances and compounds and salts derived therefrom and such as phospholipids and other lipids, bile acids and their salts, ascorbic acid and its esters such as ascorbic acid-6-palmitate, sodium lauryl sulfate, urea, salicylic acid, glycerol but also polyethylene glycols of different Molecular weights (DE 10 2007 036 685.1)
  • auxiliaries can be added to the coating medium or applied previously or subsequently to the surface of the support to be coated. Preference is given to mass ratios of active ingredient to excipient of from 100: 1 to 1:10, particular preference to ratios of from 10: 1 to 1: 1.
  • the suitable coating methods correspond to the state of the art.
  • a coating is possible by dipping in a suitable liquid (solution, emulsion, suspension, etc.) or semi-liquid (gel, paste, cream, etc.) preparation, spraying, brushing, pipetting and the use of various volume measuring devices for the exact dosage of the applied active ingredient.
  • Dry ingredients can be precisely dosed by electrostatic process are applied and held by an adhesive or roughened or textured surface.
  • Particularly preferred are threads, brushes, tufts, sponges, etc., which carry a coating in the outer, ie peripheral, region of the usually circular cross-section of the distal element, ie, distally of the central longitudinal axis.
  • a coating of the outer area is achieved, for example, by tangential spraying or by rolling the distal element via an adhesive active substance-containing paste.
  • Lumens need. These are, above all, not narrowed vessels or vessels with non-flow-limiting stenoses, with inflammatory wall changes, microbial arteriosclerosis; Other relevant applications are
  • excipients may be used wherever local administration of drugs is desired and the site of administration is not readily accessible from the outside. Examples are all gait systems such as bronchi, bile ducts, ureters etc, smaller body cavities but also the local tumor therapy, possibly in addition to other locally effective methods.
  • FIG. 1 shows a device 1 according to the invention for the application of active substances to a vessel wall with a guide wire 2, a distal element 3, which is equipped with a brush structure which consists of a platinum metal core 5 with radially protruding bristles or filaments 4.
  • the core 5 may be formed as a micro spiral, in which the filaments 4 are clamped or glued.
  • the device 1 is advanced by a catheter 6 to the site.
  • the active substance 7 is located at the outer end of the filaments 4, shown in the form of small aggregates or lumps.
  • the invention is further illustrated by the following examples.
  • the examples relate to coatings of the brush-shaped components as described in WO 2006/021407 and WO 2008/034615.
  • the surfaces of other geometric shapes and functional structures can be coated in a similar or analogous manner with drugs, as is apparent from the general description.
  • Coating Horizontal positioning of the long axis of the Phenox Clot Retriewer and slow, even rotation about the longitudinal axis; Apply 17 ⁇ l of the coating solution using a 25 ⁇ l Hamilton microsyringe (Bonaduz / switzenand), moving the tip of the syringe needle evenly from distal to proximal and back in the area of the brush.
  • Hamilton microsyringe (Bonaduz / switzenand)
  • Coating solution 0.45 ml ethanol + 100 ⁇ l aqueous solution of the iodinated X-ray contrast agent lopamidol (755 mg / ml) + 4.45 ml acetone + 250 mg paclitaxel
  • Coating solution 50 mg rapamycin in 1 ml ethanol
  • Plasticizer methanol / acetonitrile / water, 30% / 52% / 18% (v / v / v). Flow rate: 1 ml / min

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention concerne un dispositif d'application de substances actives sur la paroi d'un vaisseau corporel, afin de réaliser le traitement de la paroi du vaisseau, avec un cathéter, un élément de guidage et un élément distal implanté sur l'élément de guidage. L'élément distal est doté d'une surface atraumatique, souple et pouvant s'adapter à la paroi du vaisseau, qui porte la substance active et qui tend à prendre après la sortie du cathéter un diamètre supérieur au diamètre maximal du vaisseau dans le segment à traiter du vaisseau corporel. L'augmentation du diamètre est obtenue par des forces élastiques dans l'élément distal.
PCT/EP2010/001482 2009-03-10 2010-03-10 Dispositif d'application de substances actives sur la paroi d'un vaisseau corporel Ceased WO2010102796A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200910011931 DE102009011931A1 (de) 2009-03-10 2009-03-10 Vorrichtung zur Applikation von Wirkstoffen auf die Wand eines Körpergefäßes
DE102009011931.0 2009-03-10

Publications (2)

Publication Number Publication Date
WO2010102796A2 true WO2010102796A2 (fr) 2010-09-16
WO2010102796A3 WO2010102796A3 (fr) 2010-12-29

Family

ID=42211905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/001482 Ceased WO2010102796A2 (fr) 2009-03-10 2010-03-10 Dispositif d'application de substances actives sur la paroi d'un vaisseau corporel

Country Status (2)

Country Link
DE (1) DE102009011931A1 (fr)
WO (1) WO2010102796A2 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023787A1 (fr) 1993-04-22 1994-10-27 Rammler David H Catheter a ballon de prelevement
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
WO1998024427A2 (fr) 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions et procedes pour traiter ou prevenir les maladies inflammatoires
WO1999062510A2 (fr) 1998-06-01 1999-12-09 Angiotech Pharmaceuticals, Inc. Compositions renfermant des agents anti-microtubules pour le traitement ou la prevention de maladies inflammatoires
US6146358A (en) 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
WO2004028582A1 (fr) 2002-09-20 2004-04-08 Ulrich Speck Dispositif medical destine a la distribution d'un medicament
WO2006021407A2 (fr) 2004-08-23 2006-03-02 Phenox Gmbh Dispositif d'ablation de thrombi
DE102004046244A1 (de) 2004-09-22 2006-03-30 Orlowski, Michael, Dr. Beschichtetes Coronarstentsystem
US7179251B2 (en) 2001-01-17 2007-02-20 Boston Scientific Scimed, Inc. Therapeutic delivery balloon
WO2008034615A2 (fr) 2006-09-20 2008-03-27 Phenox Gmbh Dispositif conçu pour retirer des thrombus de vaisseaux sanguins
US20080118544A1 (en) 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5535756A (en) * 1994-01-06 1996-07-16 Parasher; Vinod K. Catheter with simultaneous brush cytology and scrape biopsy capability
US5554114A (en) * 1994-10-20 1996-09-10 Micro Therapeutics, Inc. Infusion device with preformed shape
US6725492B2 (en) * 1998-11-25 2004-04-27 Neosci Medical, Inc. Cleaning brush for medical devices
DE102007036685A1 (de) 2007-08-03 2009-02-05 Innora Gmbh Verbesserte arzneimittelbeschichtete Medizinprodukte deren Herstellung und Verwendung

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146358A (en) 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
WO1994023787A1 (fr) 1993-04-22 1994-10-27 Rammler David H Catheter a ballon de prelevement
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
WO1998024427A2 (fr) 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions et procedes pour traiter ou prevenir les maladies inflammatoires
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
WO1999062510A2 (fr) 1998-06-01 1999-12-09 Angiotech Pharmaceuticals, Inc. Compositions renfermant des agents anti-microtubules pour le traitement ou la prevention de maladies inflammatoires
US7179251B2 (en) 2001-01-17 2007-02-20 Boston Scientific Scimed, Inc. Therapeutic delivery balloon
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
WO2004028582A1 (fr) 2002-09-20 2004-04-08 Ulrich Speck Dispositif medical destine a la distribution d'un medicament
WO2006021407A2 (fr) 2004-08-23 2006-03-02 Phenox Gmbh Dispositif d'ablation de thrombi
DE102004046244A1 (de) 2004-09-22 2006-03-30 Orlowski, Michael, Dr. Beschichtetes Coronarstentsystem
WO2008034615A2 (fr) 2006-09-20 2008-03-27 Phenox Gmbh Dispositif conçu pour retirer des thrombus de vaisseaux sanguins
US20080118544A1 (en) 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices

Also Published As

Publication number Publication date
WO2010102796A3 (fr) 2010-12-29
DE102009011931A1 (de) 2010-09-16

Similar Documents

Publication Publication Date Title
EP2216055B2 (fr) dispositif medical pour l'administration de medicaments
DE60303705T2 (de) Beschichteter Stent für die Freisetzung aktiver Substanzen
EP2678466B1 (fr) Implant équipé de non-tissé
US20030181975A1 (en) Stent
DE102008061536A1 (de) Medizintechnischer Saugkörper, insbesondere zur Entfernung von Wundflüssigkeiten aus menschlichen und/oder tierischen Körperhöhlen
WO2008086794A2 (fr) Produit médical destiné à traiter des occlusions de voies corporelles et à prévenir les risques de nouvelle formation de l'occlusion
DE19843254C2 (de) Verwendung von Polymermischungen, die Cyanacrylat oder Methylenmalonester enthalten, zur Beschichtung medizinischer Geräte und Implantate, medizinische Implantate und Verfahren zu ihrer Herstellung
DE102008061535A1 (de) Medizintechnischer Saugkörper, insbesondere zur Entfernung von Wundflüssigkeiten aus menschlichen und/oder tierischen Körperhöhlen, und Verfahren zu seiner Herstellung
US20110022026A1 (en) Methods and Devices for Delivering Drugs Using Drug-Delivery or Drug-Coated Guidewires
WO2010102796A2 (fr) Dispositif d'application de substances actives sur la paroi d'un vaisseau corporel
DE102019116791B4 (de) Stent mit sofort ablösbarer Beschichtung
WO2015022366A1 (fr) Agent contenant des microparticules, servant à nettoyer et à protéger des surfaces techniques
WO2021148445A1 (fr) Produit médicinal pour libération de médicament à effet amélioré
CA2989103A1 (fr) Aiguille de biopsie de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10713557

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10713557

Country of ref document: EP

Kind code of ref document: A2